Introduction: Few randomized controlled trials have compared new treatments for metastatic melanoma. We sought to examine the relative treatment effect of talimogene laherparepvec compared with ipilimumab and vemurafenib.
understanding of the relative effect of treatment on survival in a more comparable patient population. The results of this analysis suggest that OS with talimogene laherparepvec is at least as good as with ipilimumab and vemurafenib and improvement was more pronounced in patients with no bone, brain, lung or other visceral metastases.
INTRODUCTION
Melanoma is a rare but serious form of skin cancer that can rapidly infiltrate the deep, vascular skin layers and often metastasizes very early. Data from real-world clinical practice consistently show that survival among patients with metastatic melanoma differs greatly by stage of disease [1] . In a study of 1682 patients with metastatic melanoma from the Surveillance, Epidemiology, and End Results (SEER) database [2] , patients with unresectable, non-visceral disease (stage IIIB or IIIC or IV M1a) had a median overall survival (OS) of 22-24 months, whereas those with visceral disease (stage IV M1b or IV M1c) had a median OS of 5-11 months.
Until 2011, the only systemic therapies for metastatic melanoma were conventional agents, such as dacarbazine, fotemustine, and interleukin-2 [3, 4] [5] . For BRAF-mutated melanomas, combination treatment with BRAF/MEK inhibitors is a recommended approach. For patients with BRAF-wild-type disease, the guidelines highlight ipilimumab as a standard first-line choice based on long-term survival benefit, but state anti-PD1 therapy is currently preferred, based on very recent trial results comparing pembrolizumab with ipilimumab. Anti-PD1 therapies are also recommended as a second-line treatment, after ipilimumab failure as well as for patients with other BRAF mutations.
Ipilimumab, a fully human, IgG1 monoclonal antibody, blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a negative regulator of T cells, and thereby augments T cell activation and proliferation [24] ; whereas vemurafenib is a potent inhibitor of mutated BRAF and has marked antitumor effects against melanoma cell lines with the BRAF V600E mutation but not against cells with wild-type BRAF [26] .
The most recently approved therapy for melanoma is talimogene laherparepvec, a novel first-in-class oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic antitumor immune responses. First, talimogene laherparepvec directly attacks cancer cells in the injected tumors, and second, it helps the immune system find and kill cancer cells throughout the body while leaving healthy cells undamaged [6] . Talimogene laherparepvec has been assessed in a Phase 3 randomized trial (OPTiM; ClinicalTrials.gov identifier:
NCT00769704) versus GM-CSF in patients with unresectable stage IIIB/C or IV melanoma.
In the treatment of metastatic melanoma, there is a lack of randomized, controlled, active comparator trials to date that would help to compare new treatments; as shown by the recent ESMO guidelines, the treatment pathway for patients at different disease stages remains unclear even as it evolves. Currently, ipilimumab and vemurafenib, being the first newer therapies to market, are the most widely used newer agents. Given that indirect treatment comparisons for newer therapies are increasingly a requirement for health technology assessment (HTA) agencies, the aim of this study was to examine the relative treatment effect of talimogene laherparepvec compared with ipilimumab and vemurafenib [7] .
METHODS

Systematic Review
Relevant trials were identified through a systematic review conducted in September 2015 of English-language studies, published since January 1990, on the efficacy and safety of treatments for metastatic melanoma. All trials were subject to a quality assessment, to identify the appropriate highest quality trials for inclusion. other studies can then be used to simulate those patients' experience and outcomes according to the index trial. In matching-adjusted indirect comparison, the index trial for which individual patient-level data are available is reweighted using propensity score-type approaches, so that it matches the characteristics of another study.
Neither of these approaches were considered feasible for this analysis due to the complexity of the prognostic information, combined with the heterogeneity in patient and trial characteristics, including need to consider disease stage, age, gender, visceral disease, brain metastases, lactate dehydrogenase (LDH) levels, in addition to any other patient or study characteristics. In the case of simulated treatment comparison there were not sufficient data for the required equations; for matching-adjusted indirect comparison, there was also a limitation in the matching across many prognostic factors, and the need to match to several studies.
For this analysis, a treatment-specific meta-analysis of absolute treatment effect was undertaken, which involved analysis of independent data on OS for talimogene laherparepvec, ipilimumab, and vemurafenib in each published study, but separate analyses of each drug at a time. No attempt was made at network meta-analysis, following the assessment using the Cope framework.
However, the outcomes of each relevant treatment arm in the studies used were adjusted for heterogeneity in prognostic factors (i.e., external data were adjusted accordingly to their baseline characteristics), to be comparable to the OPTiM trial. Adjustments were made using a published algorithm [13, 14] . Kaplan-Meier (KM) data were simulated at each time point for T TRIAL , assuming it had the patient population of T TVEC , which was
If a drug was studied in more than one trial included in the analysis, the data from each trial were combined so that all survival data on that drug were included in the comparison. To do this, OS data were adjusted using the modified Korn model and were then pooled across studies using the Mantel-Haenszel method [15, 16] , a fixed-effect model primarily for dichotomous outcomes that can be implemented in modeling survival counts by transformation of the survival data into hazards, or risks, period by period.
The procedure for this involves two stages: first, producing data containing events and non-events such that odds can be calculated; these data were then combined across studies to produce a pooled survival estimate. The data were not combined automatically on the basis of the single curve for survival; rather, the Mantel-Haenszel method combines the rates of death and censoring, across all studies, at each time point, and the Mantel-Haenszel survival curve is calculated from the resultant data.
Detailed procedures/steps involved are as follows:
1. Each study's KM data (unadjusted and adjusted) were broken out using the Parmar algorithm [17, 18] , to produce estimates, for each time period (in our analysis this was 1 month), of the number of patients at risk, the number of events (i.e., death or progression, depending upon whether OS data were being analyzed) and the number of censored data points. 2. In each time interval, the data were pooled using the Mantel-Haenszel method, which is as follows: created from E. In this method, confidence intervals also can be constructed around S(t).
Indirect Treatment Comparison of Subgroups
A subgroup indirect treatment comparison was also analyzed, comprising patients with no bone, brain, lung, or other visceral metastases (stage IIIB-IV M1a disease). For this subgroup analysis, the same methods outlined in the previous section were used.
Extracting Survival Data for Analysis
KM curves were extracted and digitized with
DigitizeIt version 2.0.3 for studies selected in the systematic review [19] . The digitized dataset of each arm of each trial included the survival probability at consecutive half-month intervals.
To establish the quality of the digitization outputs, median survival was determined for each of the digitized curves and compared with the median survival published in each study.
Compliance with Ethics Guidelines
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RESULTS
Systematic Review and Trials Included in the Indirect Treatment Comparison
The systematic review PRISMA chart is provided in the online supplementary material.
Randomized controlled trials (RCTs) were included in the meta-analysis if they were phase III trials, published since 2010, reported an OS curve and key baseline patient characteristics, and studied a licensed monotherapy agent and dose to treat patients with metastatic melanoma. These selection criteria were chosen to reflect the introduction of recent melanoma treatments (ipilimumab and vemurafenib), for which clinical trial publications are available only from 2010. Among the RCTs identified, four met the inclusion criteria and were included in the final indirect treatment comparisons: two for ipilimumab, one for vemurafenib, and one for talimogene laherparepvec (Table 2) . 
Overall Survival: All Patients
The prognostic patient characteristics used in the adjustments for each trial are presented in Table 3 . Table 3 shows that adjustment factors ranged between 0.53 and 0.72 and were more closely clustered within each of the two patient populations (overall and subgroup); however, the results do suggest that adjustment using the modified Korn model had a material impact.
Unadjusted and adjusted median OS for each comparator are presented in show difference in long-term survival, even after adjustment. As with the results in Table 4 , the adjustment has increased survival for ipilimumab and vemurafenib in all cases.
Overall Survival: Patients with no Visceral Metastases (Stage IIIB-IV M1a Disease)
For the subgroup analysis of patients with no bone, brain, lung or other visceral metastases (stage IIIB-IV M1a disease), unadjusted and adjusted median OS values for each comparator are presented in Table 4 . A consistently higher adjustment for patients with no bone, brain, lung, or other visceral metastases (stage IIIB-IV (Figs. 2, 3, 4 ). This is predictable in that OS is expected to be longer for patients with no visceral disease than for those with visceral disease.
Considering the 95% confidence intervals around the adjusted data, the talimogene Successive health technology appraisals of treatments for patients with metastatic melanoma have previously determined that adjusted indirect treatment comparison with the use of network meta-analysis is not feasible for metastatic melanoma [14, 20, 21] .
We undertook an indirect treatment comparison using the modified Korn model, in which patient and disease characteristics are adjusted so that all trials reflect one reference trial in terms of key patient characteristics-in this case the pivotal talimogene laherparepvec clinical trial. This approach helps to overcome issues around generalizability and transferability of results between and across trials.
To our knowledge, this is the first treatment-specific meta-analysis of independent survival curves for metastatic melanoma that includes recently available therapies and that attempts to account for significant confounders such as stage of disease. The results from this analysis showed that the OS with talimogene laherparepvec appears to be at least as good as OS with ipilimumab and vemurafenib. OS was higher for patients treated with talimogene laherparepvec than with ipilimumab or vemurafenib after adjusting for differences in patient demographic and clinical characteristics across clinical trials; this improvement was 
